Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The clinical course of common bile duct stone clearance with endoscopic retrograde cholangio-pancreaticography

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gastric peptides - gastrin and somatostatin

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Recent randomized and controlled trials of drugs derived from the gut hormone glucagon-like peptide-1 (GLP-1) show that the most frequent adverse symptoms are gastrointestinal, including gallbladder-related side effects such as cholithiasis and cholecystitis. Since the gut hormone cholecystokinin (CCK) stimulates bile secretion and regulates gallbladder motility and emptying, we examined the effect of GLP-1 on the secretion of CCK in normal subjects and patients with type 1 diabetes mellitus.

MATERIALS AND METHODS: Plasma was sampled from 10 healthy subjects and 10 patients with diabetes. With plasma glucose concentrations clamped between 6 and 9 nmol/l, GLP-1 or saline was infused for 240 min during and after a meal. The plasma concentrations of CCK were measured with a highly specific radioimmunoassay.

RESULTS: Basal plasma concentrations of CCK were similar in the normal subjects and in the diabetes patients. During the meal, the CCK concentrations rose significantly during saline infusion, whereas the GLP-1 infusion suppressed the secretion of CCK significantly in both normal subjects and in the diabetes patients.

CONCLUSIONS: The results show that GLP-1 suppresses the secretion of CCK after a meal in normal and diabetic subjects. The suppression attenuates the gallbladder contractility. Our data, therefore, offer an explanation for the increased risk of adverse gallbladder events during treatment with GLP-1-derived drugs.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume53
Issue number12
Pages (from-to)1429-1432
ISSN0036-5521
DOIs
Publication statusPublished - 2018

ID: 55656707